<DOC>
	<DOCNO>NCT02322086</DOCNO>
	<brief_summary>This multicenter study subject mild moderate psoriasis . Subjects apply PH-10 vehicle daily 28 consecutive day follow active PH-10 daily 28 consecutive day plaque psoriasis area trunk extremity ( exclude palm , sol , scalp , facial intertriginous site ) . Biopsies one target plaque collect baseline ( least 7 day prior first study treatment Day 1 ) Days 29 64 , 7-day interval biopsy Day 29 commencement application application active PH-10 Day 36 . Study data subject serve internal control ( i.e. , assessment baseline end application PH-10 vehicle ) assessment clinical cellular response active investigational agent .</brief_summary>
	<brief_title>A Phase 2 Study Cellular Immunologic Changes Skin Subjects Receiving PH-10</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Men woman , age 18 older . Presence mild moderate plaque psoriasis trunk extremity ( exclude palm , sol , scalp , facial intertriginous area ) . At least one target plaque minimum diameter 5 cm ( 2 inch ) uniform mild moderate plaque psoriasis . Fitzpatrick skin type IVI . Written inform consent subject legal guardian . Female subject childbearing potential pregnant , attempt conceive , use effective contraception , nurse infant . Subjects receive PH10 . Subjects receive PUVA systemic antipsoriatic therapy ( immunosuppressant , cytostatics , corticosteroid ) within 28 day study initiation ( 14 day methotrexate ) . Subjects received UVB light therapy within 14 day study initiation . Subjects received topical antipsoriatic therapy ( include corticosteroid , tar , anthralin Vitamin D analog ) study plaque area within 14 day study initiation . Subjects receive approved investigational biologic drug therapy psoriasis within 90 day 5 halflives study initiation . Subjects participate clinical research study within 28 day study initiation . Subjects history porphyria , systemic lupus erythematosus xeroderma pigmentosum . Subjects clinical condition , opinion Investigator , may pose health risk subject involvement study detrimentally affect regular followup subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>